Related Experiment Video
Updated: Oct 19, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions
D J Greenblatt1, L L von Moltke, J S Harmatz
1Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and New England Medical Center, Boston, Massachusetts 02111, USA. Dgreenblatt@Infonet.tufts.edu
Abstract:
The appearance of selective serotonin reuptake inhibitor antidepressants in the mid-1980s caused the discipline of clinical psychopharmacology to refocus attention to the topics of drug metabolism and drug interactions. This article reviews the metabolic profiles of some newer antidepressants, the clinical implications of metabolic properties, and research methodology that can be applied in determining which specific human cytochromes P450 (CYP) mediate metabolic pathways. Also reviewed are the relative activities of various new antidepressants as inhibitors of CYPs, and the benefits and drawbacks of in vivo and in vitro methodologies for identification and quantitation of drug interactions.
Related Concept Videos
Antidepressant Drugs: Overview
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Pharmacokinetics: Drug–Drug Interactions
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Antidepressant Drugs: MAOIs and Other Agents
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
